Disease Spotlight: Prostate Cancer

Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerging theranostics be effective in other targets beyond PSMA? Daniel George, M.D., addressed these topics and more in a recent interview.

Emerging PSMA PET-based nomograms offered 12 percent and 14 percent higher AUCs than the European Association of Urology risk score for risk stratification of patients with biochemical recurrence of prostate cancer, according to an international, registry-based study involving over 11,000 patients.

New MRI research suggests that adjunctive AI may lead to a significant reduction of unnecessary prostate biopsies.

In comparison to 68Ga-PSMA-11, 64Cu-SAR-bisPSMA more than doubled the rate of detection for prostate cancer recurrence and facilitated changes to the treatment plan in 44 percent of patients, according to research to be presented at the upcoming European Association of Urology (EAU) Congress.

Researchers found that PSMA PET/CT offered 18 percent higher accuracy than mpMRI in detecting bilateral intraprostatic disease, according to a new study involving patients with intermediate or high-risk prostate cancer.

A high SUVmean on PSMA PET imaging was associated with 95 more days of mean progression-free survival (PFS) in contrast to those with a low median SUVmean, according to a new study of patients with mCRPC treated with (225Ac)Ac-PSMA-I&T.

Employing AI-powered automation, the MIM LesionID™ Pro reportedly bolsters the efficiency of whole-body tumor burden analysis with PSMA PET/CT and SPECT/CT.

The use of 5T prostate MRI offered significantly higher signal-to-noise ratio (SNR) than 3T prostate MRI as well as enhanced delineation with T2-weighted and diffusion-weighted imaging, according to newly published comparative research.

In recent interviews, Rajesh Bhayana, M.D., Manisha Bahl, M.D., and Jeremie Calais, M.D., Ph.D., shared their thoughts on agentic AI, key directions in breast imaging research and emerging trends with prostate cancer theranostics in 2026.

Catch up on the most well-viewed prostate cancer imaging content from 2025.

Preliminary research has shown that the Vanquish Water Vapor Ablation System eliminated MRI-visible intermediate-risk PCa in over 90 percent of patients.

Utilizing the AI-enabled TrackPSMA to monitor the effectiveness of radioligand therapy for prostate cancer may allow more timely decisions to adjust treatment dosage or switch to a more effective modality.

In a prospective study comparing PSMA PET/CT and mpMRI for biopsy- and imaging-naïve men with suspected prostate cancer (PCa), PSMA PET/CT led to altered management in 34 percent of confirmed cases of PCa.

In a new review from the European Society of Urogenital Radiology (ESUR), researchers discuss the merits and limitations of PSMA PET/CT and whole-body MRI (WB-MRI) for patients with advanced prostate cancer.

Researchers found no statistically significant differences between bpMRI and mpMRI evaluations of patients with PI-RADS 3 presentations, according to a new multi-reader study.

Catch up on the most-well viewed prostate cancer imaging content in October 2025.

Pluvicto in combination with the standard of care led to a 28 percent reduction in the risk of radiographic progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results from the phase III PSMAddition trial presented at the European Society for Medical Oncology (ESMO) conference.

While a new meta-analysis of the PI-RADS v2.1 criteria showed 96 percent and 88 percent sensitivity rates for PI-RADS category > 3 and PI-RADS category > 4 assessments respectively, researchers noted a high risk of bias in 29 percent of the reviewed studies.

In the second part of a recent interview, Emmanuel S. Antonarakis, M.D. discusses PSMA PET agents in current trials and cell surface proteins that may offer targeting utility in prostate cancer imaging beyond PSMA.

In the 160-patient study comparing 18F-PSMA 1007 PET/CT and 18F-NaF PET/CT, the use of 18F-PSMA PET/CT led to 38 patients being restaged as having more advanced prostate cancer.

In a recent interview, Emmanuel S. Antonarakis, M.D. discussed contributing factors to the recent American Cancer Society report about rising prostate cancer incidence and offered insights about the potential role of the radioligand agent 177Lu-PSMA-I&T for patients with mCRPC.

PSMA PET offered 18 percent higher accuracy for detecting biochemical recurrence of PCa in contrast to mpMRI, according to findings from a 67-study meta-analysis.

Abbreviated biparametric MRI demonstrated nearly equivalent detection rates for clinically significant and clinically insignificant prostate cancer as multiparametric MRI, according to research involving 22 centers in 12 countries.

New research shows that over 94 percent of patients who had a PSA level of < 0.2 ng/mL and low-volume disease assessment six months after initiation of apalutamide and androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer had radiographic progression-free survival at 24 months.

Catch up on the most-well viewed prostate imaging content in August 2025.